Studies of Immune Responses in Candida vaginitis
The widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-10-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-0817/4/4/697 |
| _version_ | 1798034735610462208 |
|---|---|
| author | Flavia De Bernardis Silvia Arancia Silvia Sandini Sofia Graziani Sandro Norelli |
| author_facet | Flavia De Bernardis Silvia Arancia Silvia Sandini Sofia Graziani Sandro Norelli |
| author_sort | Flavia De Bernardis |
| collection | DOAJ |
| description | The widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role in the induction of mucosal immunity against C. albicans and the interaction between innate and adaptive immunity. Our studies evidenced the elicitation of cell-mediated immunity (CMIs) and antibody (Abs)-mediated immunity with a Th1 protective immunity. An immune response of this magnitude in the vagina was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Overall, our data provide clear evidence that it is possible to prevent C. albicans vaginal infection by active intravaginal immunization with aspartyl proteinase expressed as recombinant protein. This opens the way to a modality for anti-Candida protection at the mucosa. The recombinant protein Sap2 was assembled with virosomes, and a vaccine PEVION7 (PEV7) was obtained. The results have given evidence that the vaccine, constituted of virosomes and Secretory aspartyl proteinase 2 (Sap2) (PEV7), has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. |
| first_indexed | 2024-04-11T20:48:22Z |
| format | Article |
| id | doaj.art-86e0e85c60964e299a9ab270584012e9 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-04-11T20:48:22Z |
| publishDate | 2015-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-86e0e85c60964e299a9ab270584012e92022-12-22T04:03:57ZengMDPI AGPathogens2076-08172015-10-014469770710.3390/pathogens4040697pathogens4040697Studies of Immune Responses in Candida vaginitisFlavia De Bernardis0Silvia Arancia1Silvia Sandini2Sofia Graziani3Sandro Norelli4Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, ItalyDepartment of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, ItalyDepartment of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, ItalyDepartment of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, ItalyDepartment of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, ItalyThe widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role in the induction of mucosal immunity against C. albicans and the interaction between innate and adaptive immunity. Our studies evidenced the elicitation of cell-mediated immunity (CMIs) and antibody (Abs)-mediated immunity with a Th1 protective immunity. An immune response of this magnitude in the vagina was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Overall, our data provide clear evidence that it is possible to prevent C. albicans vaginal infection by active intravaginal immunization with aspartyl proteinase expressed as recombinant protein. This opens the way to a modality for anti-Candida protection at the mucosa. The recombinant protein Sap2 was assembled with virosomes, and a vaccine PEVION7 (PEV7) was obtained. The results have given evidence that the vaccine, constituted of virosomes and Secretory aspartyl proteinase 2 (Sap2) (PEV7), has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis.http://www.mdpi.com/2076-0817/4/4/697Candida vaginitisimmune responseaspartyl proteinasemucosal anti-Candida vaccine |
| spellingShingle | Flavia De Bernardis Silvia Arancia Silvia Sandini Sofia Graziani Sandro Norelli Studies of Immune Responses in Candida vaginitis Pathogens Candida vaginitis immune response aspartyl proteinase mucosal anti-Candida vaccine |
| title | Studies of Immune Responses in Candida vaginitis |
| title_full | Studies of Immune Responses in Candida vaginitis |
| title_fullStr | Studies of Immune Responses in Candida vaginitis |
| title_full_unstemmed | Studies of Immune Responses in Candida vaginitis |
| title_short | Studies of Immune Responses in Candida vaginitis |
| title_sort | studies of immune responses in candida vaginitis |
| topic | Candida vaginitis immune response aspartyl proteinase mucosal anti-Candida vaccine |
| url | http://www.mdpi.com/2076-0817/4/4/697 |
| work_keys_str_mv | AT flaviadebernardis studiesofimmuneresponsesincandidavaginitis AT silviaarancia studiesofimmuneresponsesincandidavaginitis AT silviasandini studiesofimmuneresponsesincandidavaginitis AT sofiagraziani studiesofimmuneresponsesincandidavaginitis AT sandronorelli studiesofimmuneresponsesincandidavaginitis |